Search Results

Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine.

Entos Pharmaceuticals, (Entos), a genetic medicines company pioneering the development of life-changing medicines to patients with its Fusogenix PLV nucleic acid delivery technology, will be participating in the 2024 Bloom Burton & Co. Healthcare

Entos Pharmaceuticals announced the launch of its new Good Manufacturing Practices manufacturing facility in Carlsbad, California.

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline.

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, announced the opening of its new 9,600 square foot research and development facility in the Torrey Pines community of San Diego, California.